NCT01372163 - A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

PF-05190457 or Placebo

Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.

DRUG

PF-05190457 or Placebo

Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.

DRUG

PF-05190457 or Placebo

Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.

DRUG

PF-05190457 or Placebo

Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.

DRUG

PF-05190457 or Placebo

Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.

DRUG

PF-05190457 or Placebo

Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.

DRUG

PF-05190457 or Placebo

Once (or twice) daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast (and dinner if twice) in Type 2 Diabetic patients.

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven